Palatin Technologies, Inc. (PTN)
- Insider Monkey
10 Micro-Cap Healthcare Stocks Insiders Are Buying
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]
- Zacks
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
- PR Newswire
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS).
